Daraxonrasib doubles survival for pancreatic cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Daraxonrasib patients lived nearly twice as long as those receiving standard chemotherapy in a pivotal KRAS‑G12C pancreatic cancer trial.
- Daraxonrasib results were presented at the American Society of Clinical Oncology plenary session and simultaneously published in the New England Journal of Medicine.
- Daraxonrasib prompted a strong emotional reaction from pancreatic cancer specialist Rachna Shroff, who said she cried upon hearing the data.
Why it matters: Patients see a ~100% increase in survival; the result shifts standard of care and opens a new revenue stream for Revolution Medicines, potentially improving outcomes for thousands of pancreatic cancer patients.
